Table 1. Demographic data and disease characteristics.

		Onapristone Dose
	Overall (n = 52)	10 mg BID (n = 12 a)	20 mg BID (n = 12 a)	30 mg BID (n = 6)	40 mg BID (n = 10)	50 mg BID (n = 6)	100 mg QD (n = 6)
Age (years)
Median	64	67	63	65	65	63	61
Range	36–84	42–81	36–78	59–68	45–82	46–84	53–77
Race n(%)
White	52 (100)	12 (100)	12 (100)	6 (100)	10 (100)	6 (100)	6 (100)
BMI (kg/m2)
Median	25 b	25	23	26 b	25	25	26
Range	18–35 b	19–35	18–35	20–32 b	20–35	20–26	22–29
Weight (kg)
Median	66	68	63	65	68	61	65
Range	40–91	45–86	40–78	50–91	46–90	52–66	51–72
ECOG status [n(%)]
0	23 (44)	7 (58)	4 (33)	2 (33)	3 (30)	4 (67)	3 (50)
1	29 (56)	5 (42)	8 (67)	4 (67)	7 (70)	2 (33)	3 (50)
Primary tumor [n(%)]
Breast	20 (38)	5 (42)	5 (42)	2 (33)	5 (50)	3 (50)	0
Ovarian	13 (25)	4 (33)	3 (25)	1 (17)	4 (40)	1 (17)	0
Endometrium	13 (25)	3 (25)	3 (25)	1 (17)	0	1 (17)	5 (83)
Other c	6 (12)	0	1 (8)	2 (33)	1 (10)	1 (17)	1 (17)
Metastatic sites [n (%)]
Lymph nodes	28 (54)	7 (58)	6 (50)	3 (50)	5 (50)	3 (50)	4 (67)
Liver	26 (50)	6 (50)	6 (50)	4 (67)	6 (60)	3 (50)	1 (17)
Bone	23 (44)	5 (42)	5 (42)	5 (83)	4 (40)	4 (67)	0
Peritoneum	20 (39)	4 (33)	7 (58)	2 (33)	4 (40)	1 (17)	2 (33)
Lung	15 (29)	3 (25)	5 (42)	2 (33)	1 (10)	2 (33)	2 (33)
Pleura	8 (15)	3 (25)	2 (17)	0	2 (20)	0	1 (17)
Ovarian	2 (4)	1 (8)	1 (8)	0	0	0	0
Spleen	4 (8)	1 (8)	0	1 (17)	0	0	2 (33)
Other	16 (31)	4 (33)	4 (33)	1 (17)	4 (40)	1 (17)	(33)

a. 1 patient randomized to 20mg was treated at 10mg BID and is included in all data tables as being at the 10mg dose level

b. 1 patient missing BMI (minor protocol deviation)

c. 2 uterine leiomyosarcomas, 2 endometrial stromal sarcomas, 1 uterine cancer, 1 vertex apocrine carcinoma